Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
CRO
Crown stays put as $204M Adicon deal falls through
Crown originally planned to transfer all its shares to a subsidiary of Adicon Holdings before the parties mutually agreed to end the pact.
Marissa Russo
Nov 19, 2026 4:55pm
Novartis CEO says shareholders ‘happy overall’ despite setbacks
Nov 19, 2026 4:16am
Big Pharmas tell Fierce's London event about their ideal biotech
Nov 18, 2026 5:18am
Lilly gets fresh myelofibrosis option via $1.5B Calytrix buyout
Nov 16, 2026 9:49am
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo
Nov 16, 2026 9:40am
Flagship AI-based biotechs Valo, Montai tie the knot
Nov 11, 2026 2:30pm